ArticleCancer drug resistance (Alhambra, Calif.)2025

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer.

Shuangshuang Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.